PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.

Patrick M. Forde,Zhuoxin Sun,Valsamo Anagnostou,Hedy L. Kindler,William T. Purcell,Bernardo H. L. Goulart,Arkadiusz Z. Dudek,Hossein Borghaei,Julie R. Brahmer,Suresh S. Ramalingam

PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.

2020

Patrick M. Forde
Zhuoxin Sun
Valsamo Anagnostou
Hedy L. Kindler
William T. Purcell
Bernardo H. L. Goulart
Arkadiusz Z. Dudek
Hossein Borghaei
Julie R. Brahmer
Suresh S. Ramalingam

9003Background: First-line CP was FDA-approved in 2004 for unresectable MPM. Given the role of inflammation in MPM and promising responses to PD-1 pathway blockade in pretreated MPM, we conducted a...

Keywords:

Cisplatin
Pemetrexed
multicenter study
Internal medicine
Durvalumab
Oncology
anti pd 1
pleural mesothelioma
Pathology
first line treatment
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations